Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Autor: Johnston, Stephen R D *, Toi, Masakazu, O'Shaughnessy, Joyce, Rastogi, Priya, Campone, Mario, Neven, Patrick, Huang, Chiun-Sheng, Huober, Jens, Jaliffe, Georgina Garnica, Cicin, Irfan, Tolaney, Sara M, Goetz, Matthew P, Rugo, Hope S, Senkus, Elzbieta, Testa, Laura, Del Mastro, Lucia, Shimizu, Chikako, Wei, Ran, Shahir, Ashwin, Munoz, Maria, San Antonio, Belen, André, Valérie, Harbeck, Nadia, Martin, Miguel
Zdroj: In The Lancet Oncology January 2023 24(1):77-90
Databáze: ScienceDirect